The effect of intravenous somatostatin on prevention of pancreatitis after ERCP (Endoscopic Retrograde Cholangio-Pancreatography)

Effect of intravenous somatostatin on prevention of pancreatitis after ERCP (Endoscopic Retrograde Cholangio-Pancreatography) in comparison with control group

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191231045969N1

Enrollment

100

Registered

2020-02-18

Start date

2018-08-27

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pancreatitis. Acute pancreatitis

Interventions

Intervention 1: Control group: Intravenous (distilled water) injection, 5cc intravenous injection, a syringe (no content and only one code insert) given to physician assistant to slow it for 1 to 2 mi

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years Ability to sign consent Intact papillae No contraindication for somatostatin and diclofenac Having an ERCP indication

Exclusion criteria

Exclusion criteria: Sphincterotomy Acute pancreatitis Basic amylase above 200 Allergy to somatostatin and diclofenac

Design outcomes

Primary

Measure	Time frame
Acute pancreatitis after ERCP. Timepoint: 24 hours after ERCP operation. Method of measurement: Examination and testing of lipase amylase.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Nikkhah

Iran University of Medical Sciences

Nikkhah.m@iums.ac.ir+98 21 8893 7383

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026